Recent Updates
Recently added Catalysts

Racecadotril Film-Coated

Phase 1

Antidiarrheals | Small molecule | Neurology |Johnson & Johnson|Last Updated: Jul 10, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment40
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01302093Bioequivalence Between a Racecadotril Capsule and Film-Coated Tablet (FCT) to Treat Diarrhea in AdultsPHASE1 COMPLETED 40Jan 1, 2011Jan 1, 2011Jul 10, 20121 Canada
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Maximum Observed Plasma Concentration
During 24 hours following drug administration

Maximum Observed Plasma Concentration (Cmax), which is the maximum (peak) concentration (amount of drug) measurable in blood plasma after a dose is administered, measured in nanograms/milliliter (ng/mL)

Bioavailability [AUC(0-t)]
During 24 hours post-dose

Bioavailability \[AUC(0-t)\] is a measure of how much of the drug reaches the person's bloodstream within a given period of time for the body to use. The extent of product bioavailability is estimated by the area under the blood concentration vs time curve. The Area Under the Curve (AUC) is calculated by plotting the drug's blood levels on a graph at different times during the set period. The area under this curve reflects the amount of drug exposure in the set time period, calculated as hour \* nanograms (ng) per milliliter (mL).

Secondary Endpoints
Bioavailability Extrapolated to Infinity [AUC (0-∞)]
24 hours post-dose
Time of Maximum Concentration
During 24 hours post-dose
Terminal Elimination Rate Constant
During 24 hours post-dose
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelCROSSOVER
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
Experimental TabletEXPERIMENTALA single 100 mg dose of an experimental Racecadotril Film-Coated Tablet (FCT)
Marketed CapsuleACTIVE_COMPARATORA single 100 mg dose of a marketed Racecadotril capsule
Interventions
NameTypeDescription
Racecadotril Film-Coated Tablet (FCT)DRUGA single 100 mg dose of an experimental Racecadotril FCT administered orally with 240 ml of water, with a 7- day washout between visits
Racecadotril CapsuleDRUGA single 100 mg dose of a marketed Racecadotril capsule administered orally with 240 ml of water, with a 7-day washout between visits
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Male or female subjects (equal numbers of males and females) * \- Volunteers aged of at least 18 years but not older than 55 years * \- Subjects will have a Body Mass Index (BMI) greater than or equal to 18.5 and below 30 kg/m2; and a total body weight \>50 kg * \- Non- or ex-...

Countries:Canada
Unlock Eligibility Criteria